Can a Two-Drug punch erase penile cancer before surgery?
NCT ID NCT07767266
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This trial tests whether combining two drugs—pucotenlimab, which helps the immune system attack cancer, and becotatug vedotin, which delivers a toxin directly to tumor cells—can eliminate advanced penile cancer before surgery. Men with high-risk, locally advanced penile squamous cell carcinoma will receive up to four cycles of the combination, followed by surgery if possible. The main goal is to see how many patients have no cancer cells left after treatment, with additional monitoring for long-term outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pucotenlimab (an immunotherapy drug) combined with becotatug vedotin (a targeted cancer drug)
- What this could lead to
- If successful, this combination could shrink or eliminate advanced penile tumors before surgery, potentially improving long-term survival and offering a curative approach.
- What could go wrong
- This is a small, early-phase trial, so results may not apply broadly. Side effects from the drug combination could be significant, and the treatment may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PENILE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.
- Penis transplants could restore form and function for wounded warriors
- New drug combo targets HPV-Driven cancers in phase II trial
- Double antibody attack: early trial combines immune and Growth-Signal blockers against advanced cancers
- Triple immunotherapy attack shows promise against Hard-to-Treat HPV cancers
- Promising drug cocktail aims to shrink penile cancer before surgery